Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine.
about
Estimating influenza vaccine efficacy from challenge and community-based study dataNanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccineEffectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups.Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.Live attenuated and inactivated influenza vaccines in childrenIntranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.Quantifying influenza vaccine efficacy and antigenic distance.Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccineCorrelates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza VaccineLocal and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccinesCationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protectionEvaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
P2860
Q24655781-5609EA85-193F-4B0E-BA94-04D80D88B953Q30421413-9ED911BB-C80D-49FF-8A03-68AEA43C1400Q34194475-B616F6D4-B3DC-44B9-B91F-63FA1F1F7CB8Q34461309-2EB72330-127E-4E24-94ED-4D01C7F6AE8AQ34974775-8C983841-B8F3-4FF2-8B5C-730D883DC8AEQ35550710-23CFB38C-D4A3-4FA2-90C2-2DC0A273D259Q35760689-0F22154B-8198-4057-9717-093F1EB56E1CQ36746934-DF741EA0-5D59-4791-B89C-91074049C3BEQ36889707-C8D4CBCF-EE47-4210-966C-5E5CE1DFB7F0Q37091608-16C68ABD-8304-41BF-BF73-C61F1CBF8EA3Q37149005-F2C66734-5FB4-4597-9928-3583C124679EQ37212827-10906801-4576-45C8-AD2B-9FE1980F812AQ37235698-1A7FDC6C-B894-4314-8D42-E4F8BFCD9442Q37530383-642A34BE-D8A6-4C87-ACF4-02BA008572BB
P2860
Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance of adults to challe ...... or inactivated virus vaccine.
@en
Resistance of adults to challe ...... or inactivated virus vaccine.
@nl
type
label
Resistance of adults to challe ...... or inactivated virus vaccine.
@en
Resistance of adults to challe ...... or inactivated virus vaccine.
@nl
prefLabel
Resistance of adults to challe ...... or inactivated virus vaccine.
@en
Resistance of adults to challe ...... or inactivated virus vaccine.
@nl
P2093
P2860
P1476
Resistance of adults to challe ...... or inactivated virus vaccine.
@en
P2093
B R Murphy
E L Tierney
M L Clements
P2860
P407
P577
1986-01-01T00:00:00Z